Alexander Fine

Scientist in cancer genomics and computational discovery at @FoundationATCG. All opinions are my own. 🏳️‍🌈 he/him.

[Foundation Medicine @FoundationATCG]

#Research in @TheLancet showcased positive results of CUPISCO, a randomized, precision oncology study designed to prospectively assess the efficacy of molecularly guided therapy in patients w/ unfavorable subsets of cancer-of-unknown-primary. Learn more: https://t.co/08quPDOhV4

[Jay Bradner, M.D. @jaybradner]

Today in @ScienceMagazine, together with my former colleagues at NIBR, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. 1/10
https://t.co/rJypcBl75C

[Garrett Frampton @BostonGenomics]

Hot science! Look at the separation of those curves!

Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer https://t.co/C2m6GCqOzL

[Geoff Oxnard MD @geoff_oxnard]

https://t.co/tKiHrufPdh

[Foundation Medicine @FoundationATCG]

#Announcing the launch of FoundationOne®Monitor* for research use in retrospective studies - available for biopharma customers, test provides unique access to our ctDNA tumor fraction biomarker: https://t.co/Xf5nJmjBPP

*Research Use Only. Not for use in diagnostic procedures

[Nature Medicine @NatureMedicine]

A #machinelearning model that utilizes longitudinal #ctDNA metrics robustly predicts survival in two phase 3 trials of patients with metastatic #NSCLC, which may improve therapy selection and risk stratification. @genentech
https://t.co/maVoyEEyiV

[Alexander Fine @Alexander_Fine]

I am so glad to see our study published! Exciting science showing the utility of ctDNA monitoring after CH variant exclusion.

[Alexander Fine @Alexander_Fine]

I am so glad to see our study published! Exciting science showing the utility of ctDNA monitoring after CH variant exclusion.

[Geoff Oxnard MD @geoff_oxnard]

Super exciting to work with @genentech on this creative analysis in @NatureMedicine of IMpower150 demonstrating the power of ctDNA monitoring to predict outcome on chemoIO:
https://t.co/K4qxPpo30e

[Geoff Oxnard MD @geoff_oxnard]

Super exciting to work with @genentech on this creative analysis in @NatureMedicine of IMpower150 demonstrating the power of ctDNA monitoring to predict outcome on chemoIO:
https://t.co/K4qxPpo30e

[npj Journals @Nature_NPJ]

"This is probably THE largest KRAS focused mutational database across human cancers I have seen" @Aiims1742

Incredible work @oncoOuLungCA @smruthy90 @VivekSubbiah @EthanSokol @geoff_oxnard @genentech @FoundationATCG

Read in #npjPrecisionOncology 🧬🎯

https://t.co/dqKy0PvqlC

[Aadel Chaudhuri, MD PhD @aadel_chaudhuri]

Thank you for involving me in this effort!

#ctDNA pre->on-tx change across multiple platforms & NSCLC #Immunotherapy studies correlate significantly with PFS, OS, tumor response.

@CancerResrch multi-institutional harmonization collab between #academia, #pharma, @FDAOncology

[Friends of Cancer Research @CancerResrch]

IT’S HERE! Our #ctMoniTR Step 1 Manuscript was just published in @JCOPO_ASCO . Key takeaway: Our unique consortium demonstrated reductions in ctDNA are strongly associated with better clinical outcomes. What about the details? A🧵 https://t.co/mEeQGsn4nW

[Foundation Medicine @FoundationATCG]

In partnership with @flatironhealth, @genentech and a network of community oncology practices, we are excited to release new research on tumor profiling results from the ongoing Prospective Clinicogenomic (PCG) Study. More on this new data and the study: https://t.co/j3wlx541w3

[Foundation Medicine @FoundationATCG]

Proud to share that we have now delivered 1 million reports, generated from our portfolio of CGP tests. Learn more about what this means for patients and the partners we serve in a blog from our CEO, Dr. Brian Alexander (@xelamb): https://t.co/UTzU1IZVG5

[Ethan Sokol @EthanSokol]

It’s out! We identify mutual exclusivity between microsatellite instability and HRD. BRCA1/2 mutations in MSI-H tumors are predominantly monoallelic passenger alterations which may not predict PARPi sensitivity. Rather patients may benefit from ICI. https://t.co/OpbKCFPCK0

[Alexander Fine @Alexander_Fine]

I am looking for someone to come work with me at @FoundationATCG! We are hiring a Scientist to join the Cancer Genomics Research team. We're a collaborative group investigating a 500,000+ tumor sample dataset. Please share & reach out if interested! https://t.co/RI49b5JrUM

[Garrett Frampton @BostonGenomics]

Come work with me!

[Alexander Fine @Alexander_Fine]

I am looking for someone to come work with me at @FoundationATCG! We are hiring a Scientist to join the Cancer Genomics Research team. We're a collaborative group investigating a 500,000+ tumor sample dataset. Please share & reach out if interested! https://t.co/RI49b5JrUM

[Garrett Frampton @BostonGenomics]

Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care | Foundation Medicine https://t.co/nnp4yelHyZ

[Garrett Frampton @BostonGenomics]

Come work with me! You won't regret it!